Xynomic Pharma has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications
03/11/2017 news admin

March. 8, 2017 — Xynomic Pharmaceuticals, Inc., a US-China oncology startup, has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications from Resarci Therapeutics of West Lafayette, Indiana. It will be tested as a treatment for prostate, pancreatic and other solid tumors. Xynomic will pay $1.2 million in upfront and milestone payments, plus royalties that could total $59 million. Two weeks ago, Xynomic announced it had acquired global rights to abexinostat, an HDAC inhibitor targeting hematological and solid tumor cancers. Xynomic also disclosed that it is close to in-licensing a potentially best-in-class BRAF inhibitor, targeting colorectal cancer and melanoma.

Tags